1.33
前日終値:
$1.21
開ける:
$1.22
24時間の取引高:
3.50M
Relative Volume:
1.11
時価総額:
$483.32M
収益:
$1.21M
当期純損益:
$-177.12M
株価収益率:
-1.6625
EPS:
-0.8
ネットキャッシュフロー:
$-162.37M
1週間 パフォーマンス:
+22.02%
1か月 パフォーマンス:
+11.76%
6か月 パフォーマンス:
+263.98%
1年 パフォーマンス:
-15.29%
Lexicon Pharmaceuticals Inc Stock (LXRX) Company Profile
名前
Lexicon Pharmaceuticals Inc
セクター
電話
(281) 863-3000
住所
2445 TECHNOLOGY FOREST BLVD., THE WOODLANDS
LXRX を他の銘柄と比較する
株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
---|---|---|---|---|---|---|
![]()
LXRX
Lexicon Pharmaceuticals Inc
|
1.33 | 439.71M | 1.21M | -177.12M | -162.37M | -0.80 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
376.62 | 97.36B | 11.39B | 3.64B | 3.50B | 13.99 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
576.98 | 60.19B | 14.21B | 4.46B | 3.56B | 39.68 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
458.37 | 59.56B | 2.46B | -319.09M | -52.09M | -2.47 |
![]()
ARGX
Argen X Se Adr
|
729.76 | 44.94B | 3.06B | 1.28B | 447.35M | 21.30 |
![]()
ONC
Beone Medicines Ltd Adr
|
329.84 | 36.14B | 3.81B | -644.79M | -669.77M | -6.24 |
Lexicon Pharmaceuticals Inc Stock (LXRX) Upgrades & Downgrades
日付 | アクション | アナリスト | 評価の変更 |
---|---|---|---|
2025-03-05 | ダウングレード | Leerink Partners | Outperform → Market Perform |
2024-06-17 | 開始されました | H.C. Wainwright | Buy |
2024-04-30 | 開始されました | Leerink Partners | Outperform |
2023-03-07 | 開始されました | Jefferies | Hold |
2022-08-12 | 開始されました | Piper Sandler | Overweight |
2021-01-29 | アップグレード | JP Morgan | Underweight → Neutral |
2021-01-29 | ダウングレード | Wedbush | Outperform → Neutral |
2020-12-08 | アップグレード | Citigroup | Neutral → Buy |
2020-11-18 | アップグレード | Gabelli & Co | Hold → Buy |
2019-12-11 | ダウングレード | Gabelli & Co | Buy → Hold |
2019-11-08 | ダウングレード | Citigroup | Buy → Neutral |
2019-09-11 | アップグレード | Gabelli & Co | Hold → Buy |
2019-07-29 | ダウングレード | Stifel | Buy → Hold |
2019-03-25 | アップグレード | Gabelli & Co | Sell → Hold |
2018-07-31 | 繰り返されました | Stifel | Buy |
2018-02-23 | ダウングレード | Needham | Buy → Hold |
2018-02-14 | ダウングレード | JP Morgan | Neutral → Underweight |
2017-03-01 | 繰り返されました | H.C. Wainwright | Buy |
2017-03-01 | 繰り返されました | Wedbush | Outperform |
2016-10-07 | 開始されました | H.C. Wainwright | Buy |
2016-08-05 | 繰り返されました | Wedbush | Outperform |
2016-08-02 | 開始されました | Citigroup | Buy |
2016-03-02 | 繰り返されました | Wedbush | Outperform |
2015-11-09 | 繰り返されました | Wedbush | Outperform |
2015-09-28 | アップグレード | Gabelli & Co | Sell → Hold |
2015-09-18 | ダウングレード | Gabelli & Co | Hold → Sell |
2015-08-10 | ダウングレード | JP Morgan | Overweight → Neutral |
すべてを表示
Lexicon Pharmaceuticals Inc (LXRX) 最新ニュース
Lexicon Pharmaceuticals, Inc. $LXRX Shares Purchased by Compagnie Lombard Odier SCmA - MarketBeat
Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Lexicon awaits FDA feedback on diabetes drug application in Q4 By Investing.com - Investing.com Australia
Lexicon awaits FDA feedback on diabetes drug application in Q4 - Investing.com
Lexicon Pharmaceuticals (LXRX) Faces FDA Review Extension for Zy - GuruFocus
Lexicon pharmaceuticals announces update on submission of additional data to U.S. FDA - MarketScreener
Lexicon expects delay in FDA feedback on additional data for its diabetes drug - Reuters
Lexicon (LXRX) Seeks FDA Feedback on Zynquista with New Data Sub - GuruFocus
Lexicon reports FDA's decision to extend review period for Zynquista - Seeking Alpha
Lexicon Pharmaceuticals Provides Update on Zynquista NDA Resubmission Following FDA Feedback - Quiver Quantitative
Lexicon Pharmaceuticals Announces Update on Submission of Additional Data to U.S. FDA Supporting the Benefit-Risk Profile of Zynquista® in Type 1 Diabetes - The Manila Times
FDA Extends Review of Breakthrough Diabetes Drug Zynquista: What Lexicon's New Data Shows - Stock Titan
Nasdaq Moves: Whats the MACD signal for Lexicon Pharmaceuticals IncStop Loss & Verified High Yield Trade Plans - خودرو بانک
Lexicon Pharmaceuticals (NASDAQ:LXRX) Share Price Crosses Above 200-Day Moving AverageTime to Sell? - MarketBeat
Market Review: What is the target price for Lexicon Pharmaceuticals Inc stockM&A Rumor & Entry Point Strategy Guides - خودرو بانک
Guidance Update: Can Lexicon Pharmaceuticals Inc. reach all time highs this yearMarket Performance Summary & Daily Technical Forecast Reports - خودرو بانک
Geopolitics Watch: Is Lexicon Pharmaceuticals Inc a defensive stockPortfolio Gains Report & Risk Controlled Swing Alerts - خودرو بانک
What makes Lexicon Pharmaceuticals Inc. stock attractive todayWeekly Trend Recap & Reliable Intraday Trade Alerts - خودرو بانک
CEO Moves: What is Lexicon Pharmaceuticals Incs valuation compared to sectorEntry Point & Reliable Volume Spike Alerts - خودرو بانک
How volatile is Lexicon Pharmaceuticals Inc. stock2025 Market WrapUp & Weekly Return Optimization Alerts - خودرو بانک
Lexicon Pharmaceuticals (LXRX) Highlights Promising Phase 2b Stu - GuruFocus
Lexicon Pharmaceuticals Presents Promising Phase 2b Results for Pilavapadin in Treating Diabetic Peripheral Neuropathic Pain - Quiver Quantitative
2-Point Pain Reduction: Lexicon's Non-Opioid Drug Could Be First New DPNP Treatment in 20 Years - Stock Titan
Is Vistagen Therapeutics Inc. forming a bullish divergenceTake Profit & Comprehensive Market Scan Reports - خودرو بانک
Breakouts Watch: Whats the MACD signal for Lexicon Pharmaceuticals IncJuly 2025 Short Interest & Free Risk Controlled Daily Trade Plans - خودرو بانک
Aug Update: What’s the MACD signal for NHPAPEarnings Growth Report & AI Driven Stock Price Forecasts - خودرو بانک
Lexicon Pharmaceuticals jumps amid takeover speculation - MSN
Market Outlook: What’s the RSI of Lexicon Pharmaceuticals Inc. stockRecession Risk & Real-Time Volume Triggers - khodrobank.com
Panic Selling: What is Lexicon Pharmaceuticals Inc.’s TAM (Total Addressable Market)2025 Macro Impact & Weekly Market Pulse Updates - khodrobank.com
Market Review: Does Lexicon Pharmaceuticals Inc meet Warren Buffetts criteriaIPO Watch & Pattern Based Trade Signal System - خودرو بانک
Wall Street Recap: What is Kaltura Inc. s debt to equity ratioJuly 2025 Fed Impact & Weekly High Conviction Trade Ideas - khodrobank.com
Published on: 2025-09-16 15:08:33 - خودرو بانک
Buybacks Report: What drives Lexicon Pharmaceuticals Incs stock pricePortfolio Performance Summary & Safe Capital Growth Trade Ideas - خودرو بانک
Performance Recap: Will Lexicon Pharmaceuticals Inc benefit from sector rotationQuarterly Trade Report & Long-Term Capital Growth Ideas - خودرو بانک
Aug Movers: What is the target price for Lexicon Pharmaceuticals Inc stockTrade Risk Assessment & Technical Pattern Based Buy Signals - خودرو بانک
Institution Moves: Is Lexicon Pharmaceuticals Inc stock trending bullish2025 Momentum Check & Community Shared Stock Ideas - خودرو بانک
MACD Signal: Should I hold or sell Lexicon Pharmaceuticals Inc now2025 Historical Comparison & AI Forecast Swing Trade Picks - خودرو بانک
Lexicon Pharmaceuticals to Present Additional Clinical Data on Pilavapadin at Three Upcoming Medical Meetings - The Manila Times
Lexicon Pharmaceuticals Presents Promising Data on Pilavapadin for Diabetic Peripheral Neuropathic Pain at Upcoming Medical Meetings - Quiver Quantitative
Lexicon Pharmaceuticals stock maintains Buy rating at H.C. Wainwright - Investing.com
Lexicon Pharmaceuticals to Present Additional Clinical Data on Pilavapadin at Three Upcoming ... - nrtoday.com
Novel Non-Opioid Pain Drug Data: Lexicon's Pilavapadin Shows Promise for Diabetic Neuropathy Treatment - Stock Titan
Lexicon Pharmaceuticals stock maintains Buy rating at H.C. Wainwright By Investing.com - Investing.com Canada
Lexicon Pharmaceuticals stock rises as H.C. Wainwright reiterates Buy rating By Investing.com - Investing.com Canada
Lexicon Pharmaceuticals stock rises as H.C. Wainwright reiterates Buy rating - Investing.com
Lexicon Pharmaceuticals at H.C. Wainwright: Strategic Program Updates By Investing.com - Investing.com Canada
Lexicon Pharmaceuticals at H.C. Wainwright: Strategic Program Updates - Investing.com
Lexicon submits new data to FDA for potential diabetes drug approval By Investing.com - Investing.com South Africa
Lexicon Submits Additional Benefit-Risk Data to FDA for Sotagliflozin for Type 1 Diabetes - HCPLive
Lexicon submits new data to FDA for potential diabetes drug approval - Investing.com
Lexicon submits new data to FDA supporting Zynquista's use in type 1 diabetes - MarketScreener
Lexicon Pharmaceuticals Inc (LXRX) 財務データ
収益
当期純利益
現金流量
EPS
大文字化:
|
ボリューム (24 時間):